Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

NVS vs CAMP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: NVS 4 – 1 CAMP (1 Tie) Matrix Metrics: NVS 8 – 2 CAMP

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin).

  • Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (34.0% vs. -991.8% operating margin) and revenue trajectory (+4.7% vs. +138.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs CAMP
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$159.20
-0.62% 1D
Market Cap $303.1B
TTM Revenue $40.5B
Forward P/E 16.1x
Beta / 30D Vol 0.31β · 26% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 33.0 Fund 38.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.0% over 20 days), RSI 55
RSI-14: 55.1 · SMA20: $159.38 · SMA50: $149.57
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84

6-Pillar Scorecard Institutional Category Breakdown (NVS 4 – 1 CAMP)

Columns: Metric · NVS · CAMP
1. Valuation Multiples NVS
Forward P/E 16.1x N/M
Trailing P/E 30.6x N/M
PEG Ratio 3.82x N/M
EV / Revenue 7.5x 26.6x
2. Growth & Scale CAMP
Revenue Growth (YoY) +4.7% +138.9%
Earnings Growth (YoY) -68.8% +0.0%
TTM Revenue (USD) $40.5B $5.3M
Market Cap $303.1B $238.5M
3. Profitability & Quality NVS
Gross Margin 75.2% N/A
Operating Margin 34.0% -991.8%
Net Profit Margin 17.5% 0.0%
Return on Equity (ROE) 24.3% -146.1%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA -$26M
Cash Flow Margin 42.0% EBITDA Mgn N/A
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $97M Net Cash
Dividend Yield 2.95% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 16.9% (6th %ile) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (8) vs CAMP (2)
Institutional Metric NVS CAMP Criterion Row Edge
Market Capitalization
Scale
$303.1B $238.5M Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x N/M Lower Multiple NVS
Forward P/E Ratio
Valuation
16.1x N/M Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +138.9% Higher Growth CAMP
Operating Margin (TTM)
Profitability
34.0% -991.8% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 0.0% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% -146.1% Higher ROE NVS
52-Week Range Position
Momentum
76% ($123–$170) 22% ($3–$8) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
0.31β · 26% Vol 1.34β · 94% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 43.9 / 100 (HOLD) Higher Composite CAMP
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.82x PEG · 7.5x EV/Rev N/M PEG · 26.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) -$26M ($97M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +19.81 pp
NVS: +5.99% · CAMP: +25.8%
3M Horizon NVS +14.36 pp
NVS: -0.69% · CAMP: -15.05%
6M Horizon NVS +10.64 pp
NVS: +5.82% · CAMP: -4.82%
1Y Horizon NVS +24.95 pp
NVS: +21.29% · CAMP: -3.66%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs CAMP. Trailing 12-month operating profitability (NVS 34.0% vs CAMP -991.8%) and valuation multiples (NVS 16.1x vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.1x
CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $303.1B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs CAMP Key Questions & Quantitative Answers

As of Nov 17, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 42.2/100 (HOLD) at $159.20 (16.1x Forward P/E, 34.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. NVS 42.2/100 HOLD), NVS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (34.0% vs. -991.8% operating margin) and revenue trajectory (+4.7% vs. +138.9% YoY).

CAMP leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $5.3M for CAMP. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.

NVS screens cheaper on headline valuation multiples. NVS trades at 16.1x Forward P/E, 30.6x Trailing P/E, 3.82x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus CAMP (-146.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 26% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.